Literature DB >> 2213837

8-Substituted 5-[(aminoalkyl)amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones as potential antineoplastic agents. Synthesis and biological activity.

W M Cholody1, S Martelli, J Konopa.   

Abstract

A series of 8-substituted 5-[(aminoalkyl)amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones (2), structurally related to the imidazoacridinones (1), was synthesized and tested for cytotoxic and antineoplastic activity. Preliminary biological results indicated that the 8-OH derivatives possess the highest antitumor activity. No relationship has been found between the nature of the C-8 substituent and antitumor activity.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2213837     DOI： 10.1021/jm00172a028

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  15 in total

1.  The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.

Authors:  Ewa Augustin; Anna Skwarska; Anna Weryszko; Iwona Pelikant; Ewa Sankowska; Barbara Borowa-Mazgaj
Journal:  Acta Pharmacol Sin       Date:  2015-02-02       Impact factor: 6.150

2.  CYP3A4 overexpression enhances the cytotoxicity of the antitumor triazoloacridinone derivative C-1305 in CHO cells.

Authors:  Ewa Augustin; Barbara Borowa-Mazgaj; Agnieszka Kikulska; Milena Kordalewska; Monika Pawłowska
Journal:  Acta Pharmacol Sin       Date:  2012-11-19       Impact factor: 6.150

3.  Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use.

Authors:  Monika Pawlowska; Rong Chu; Barbara Fedejko-Kap; Ewa Augustin; Zofia Mazerska; Anna Radominska-Pandya; Timothy C Chambers
Journal:  Drug Metab Dispos       Date:  2012-11-16       Impact factor: 3.922

4.  Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10.

Authors:  Barbara Fedejko-Kap; Stacie M Bratton; Moshe Finel; Anna Radominska-Pandya; Zofia Mazerska
Journal:  Drug Metab Dispos       Date:  2012-06-01       Impact factor: 3.922

5.  Chemotherapeutic potential of 9-phenyl acridine: biophysical studies on its binding to DNA.

Authors:  Rita Ghosh; Sudipta Bhowmik; Angshuman Bagchi; Dipankar Das; Somnath Ghosh
Journal:  Eur Biophys J       Date:  2010-02-05       Impact factor: 1.733

6.  Combined anticancer therapy with imidazoacridinone analogue C-1305 and paclitaxel in human lung and colon cancer xenografts-Modulation of tumour angiogenesis.

Authors:  Marta Świtalska; Beata Filip-Psurska; Magdalena Milczarek; Mateusz Psurski; Adrianna Moszyńska; Aleksandra M Dąbrowska; Małgorzata Gawrońska; Karol Krzymiński; Maciej Bagiński; Rafał Bartoszewski; Joanna Wietrzyk
Journal:  J Cell Mol Med       Date:  2022-06-14       Impact factor: 5.295

7.  Physicochemical interaction of antitumor acridinone derivatives with DNA in view of QSAR studies.

Authors:  Marcin Koba; Tomasz Bączek
Journal:  Med Chem Res       Date:  2010-11-17       Impact factor: 1.965

8.  Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities.

Authors:  Krzysztof Lemke; Marcin Wojciechowski; William Laine; Christian Bailly; Pierre Colson; Maciej Baginski; Annette K Larsen; Andrzej Skladanowski
Journal:  Nucleic Acids Res       Date:  2005-10-27       Impact factor: 16.971

9.  Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer.

Authors:  A M Burger; J A Double; J Konopa; M C Bibby
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

10.  Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.

Authors:  A Skladanowski; J Konopa
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.